S&P 500   3,943.86 (+0.69%)
DOW   32,173.91 (+0.98%)
QQQ   304.70 (-0.22%)
AAPL   157.48 (+1.60%)
MSFT   270.79 (-3.09%)
META   197.26 (+0.84%)
GOOGL   101.15 (-0.46%)
AMZN   97.07 (-1.90%)
TSLA   183.47 (+1.85%)
NVDA   258.57 (+0.51%)
NIO   8.72 (+5.57%)
BABA   80.88 (-0.97%)
AMD   96.17 (-1.71%)
T   18.45 (+1.77%)
F   11.20 (-0.88%)
MU   57.20 (+0.95%)
CGC   1.87 (-6.50%)
GE   89.88 (-0.45%)
DIS   93.74 (+0.58%)
AMC   4.30 (+2.87%)
PFE   40.61 (+1.27%)
PYPL   72.61 (-0.52%)
NFLX   303.91 (+0.14%)
S&P 500   3,943.86 (+0.69%)
DOW   32,173.91 (+0.98%)
QQQ   304.70 (-0.22%)
AAPL   157.48 (+1.60%)
MSFT   270.79 (-3.09%)
META   197.26 (+0.84%)
GOOGL   101.15 (-0.46%)
AMZN   97.07 (-1.90%)
TSLA   183.47 (+1.85%)
NVDA   258.57 (+0.51%)
NIO   8.72 (+5.57%)
BABA   80.88 (-0.97%)
AMD   96.17 (-1.71%)
T   18.45 (+1.77%)
F   11.20 (-0.88%)
MU   57.20 (+0.95%)
CGC   1.87 (-6.50%)
GE   89.88 (-0.45%)
DIS   93.74 (+0.58%)
AMC   4.30 (+2.87%)
PFE   40.61 (+1.27%)
PYPL   72.61 (-0.52%)
NFLX   303.91 (+0.14%)
S&P 500   3,943.86 (+0.69%)
DOW   32,173.91 (+0.98%)
QQQ   304.70 (-0.22%)
AAPL   157.48 (+1.60%)
MSFT   270.79 (-3.09%)
META   197.26 (+0.84%)
GOOGL   101.15 (-0.46%)
AMZN   97.07 (-1.90%)
TSLA   183.47 (+1.85%)
NVDA   258.57 (+0.51%)
NIO   8.72 (+5.57%)
BABA   80.88 (-0.97%)
AMD   96.17 (-1.71%)
T   18.45 (+1.77%)
F   11.20 (-0.88%)
MU   57.20 (+0.95%)
CGC   1.87 (-6.50%)
GE   89.88 (-0.45%)
DIS   93.74 (+0.58%)
AMC   4.30 (+2.87%)
PFE   40.61 (+1.27%)
PYPL   72.61 (-0.52%)
NFLX   303.91 (+0.14%)
S&P 500   3,943.86 (+0.69%)
DOW   32,173.91 (+0.98%)
QQQ   304.70 (-0.22%)
AAPL   157.48 (+1.60%)
MSFT   270.79 (-3.09%)
META   197.26 (+0.84%)
GOOGL   101.15 (-0.46%)
AMZN   97.07 (-1.90%)
TSLA   183.47 (+1.85%)
NVDA   258.57 (+0.51%)
NIO   8.72 (+5.57%)
BABA   80.88 (-0.97%)
AMD   96.17 (-1.71%)
T   18.45 (+1.77%)
F   11.20 (-0.88%)
MU   57.20 (+0.95%)
CGC   1.87 (-6.50%)
GE   89.88 (-0.45%)
DIS   93.74 (+0.58%)
AMC   4.30 (+2.87%)
PFE   40.61 (+1.27%)
PYPL   72.61 (-0.52%)
NFLX   303.91 (+0.14%)
OTCMKTS:IPCIF

Intellipharmaceutics International - IPCIF Stock Forecast, Price & News

$0.05
-0.01 (-10.71%)
(As of 03/17/2023 08:55 PM ET)
Add
Compare
Today's Range
$0.05
▼
$0.06
50-Day Range
$0.05
▼
$0.09
52-Week Range
$0.05
▼
$0.16
Volume
30,800 shs
Average Volume
4,617 shs
Market Capitalization
$1.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IPCIF stock logo

About Intellipharmaceutics International (OTCMKTS:IPCIF) Stock

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Receive IPCIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellipharmaceutics International and its competitors with MarketBeat's FREE daily newsletter.

IPCIF Stock News Headlines

March 17, 2023 | seekingalpha.com
IPCIF Intellipharmaceutics International Inc.
March 7, 2023 | finance.yahoo.com
Intellipharmaceutics Announces Cease Trade Order
March 20, 2023 | Stansberry Research (Ad)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
February 6, 2023 | finance.yahoo.com
Intellipharmaceutics Announces its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form and its Management Cease Trade Order Application
October 15, 2022 | finanznachrichten.de
Intellipharmaceutics International Inc.: Intellipharmaceutics Announces Third Quarter 2022 Results
October 14, 2022 | finance.yahoo.com
Intellipharmaceutics Announces Third Quarter 2022 Results
July 15, 2022 | finance.yahoo.com
Intellipharmaceutics Announces Delay in Filing Second Quarter Results Due July 15, 2022, The Financial Statements Will be Filed By July 21, 2022
February 28, 2022 | finance.yahoo.com
Intellipharmaceutics Announces Fiscal Year 2021 Results
March 20, 2023 | Investing Daily (Ad)
This Trade Strategy Outpaces Almost Anything
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
January 13, 2022 | finance.yahoo.com
Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead
December 22, 2021 | finance.yahoo.com
Intellipharmaceutics Comments on Recent Trading Activity
October 16, 2021 | finanznachrichten.de
Intellipharmaceutics International Inc.: Intellipharmaceutics Announces Third Quarter 2021 Results
October 13, 2021 | businesswire.com
Kim Spencer McPhee Barristers, P.C. Publishes This Notice of Settlement Approval of the Intellipharmaceutics International Inc. Securities Class Action
June 17, 2021 | finance.yahoo.com
Intellipharmaceutics International Inc. (IPCI.TO)
April 22, 2021 | finance.yahoo.com
Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement
March 8, 2021 | finance.yahoo.com
Group Nine Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing March 8, 2021
December 30, 2020 | markets.businessinsider.com
News for IntelliPharmaCeutics International Inc Registered Shs
December 23, 2020 | finanznachrichten.de
Intellipharmaceutics International Inc.: Intellipharmaceutics Reports Director Election Results
December 23, 2020 | finance.yahoo.com
Intellipharmaceutics Reports Director Election Results
December 15, 2020 | finance.yahoo.com
Intellipharmaceutics Announces Change in Venue for The Company’s Annual General Meeting Scheduled To Be Held on December 23, 2020
October 15, 2020 | finanznachrichten.de
Intellipharmaceutics International Inc.: Intellipharmaceutics Announces Third Quarter 2020 Results
August 17, 2020 | finance.yahoo.com
Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of Intellipharmaceutics Common Stock
July 2, 2020 | finance.yahoo.com
"Intellipharmaceutics Announces That The Company And Purdue Pharma L.P. et al Have Entered Into A Stipulated Dismissal Agreement To Terminate Purdue Patent Litigation, Subject To Court Approval"
May 29, 2020 | www.finanznachrichten.de
Intellipharmaceutics International Inc.: Intellipharmaceutics Announces First Quarter 2020 Results
April 27, 2020 | www.bloomberg.com
Intellipharmaceutics Announces Receipt of Cannabis Drug License from Health Canada
April 21, 2020 | www.bloomberg.com
Intellipharmaceutics Announces FDA Approval for Generic Pristiq(R)
April 11, 2020 | www.finanznachrichten.de
Intellipharmaceutics International Inc.: Intellipharmaceutics Provides Timing of First Quarter 2020 Results
See More Headlines
Receive IPCIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellipharmaceutics International and its competitors with MarketBeat's FREE daily newsletter.

IPCIF Company Calendar

Last Earnings
7/16/2018
Today
3/20/2023
Fiscal Year End
11/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:IPCIF
CUSIP
N/A
CIK
1474835
Web
www.intellipharmaceutics.com
Phone
416-798-3001
Fax
416-798-3007
Employees
11
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,140,000.00
Net Margins
N/A
Pretax Margin
-4,007.84%
Return on Equity
N/A
Return on Assets
-244.98%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.05
Quick Ratio
0.05

Sales & Book Value

Annual Sales
$1.40 million
Price / Sales
1.18
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.25) per share
Price / Book
-0.20

Miscellaneous

Outstanding Shares
33,090,000
Free Float
32,511,000
Market Cap
$1.65 million
Optionable
Optionable
Beta
1.54

Key Executives

  • Dr. Isa Odidi MBA (Age 65)
    Ph.D., Co-Founder, Chairman, CEO & Co-Chief Scientific Officer
    Comp: $374.92k
  • Dr. Amina Odidi Ph.D. (Age 63)
    Pres, COO, Co-Chief Scientific Officer, Acting CFO & Exec. Director
    Comp: $374.92k
  • Dr. Patrick N. Yat Ph.D. (Age 65)
    Vice-Pres of Chemistry & Analytical Services
    Comp: $57.45k
  • Fazayill Shaideen
    Controller

Key Competitors

View All Competitors













IPCIF Stock - Frequently Asked Questions

How have IPCIF shares performed in 2023?

Intellipharmaceutics International's stock was trading at $0.0702 at the beginning of the year. Since then, IPCIF shares have decreased by 28.7% and is now trading at $0.05.
View the best growth stocks for 2023 here.

Are investors shorting Intellipharmaceutics International?

Intellipharmaceutics International saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 1,500 shares, an increase of 7.1% from the February 13th total of 1,400 shares. Based on an average trading volume of 4,600 shares, the days-to-cover ratio is presently 0.3 days.
View Intellipharmaceutics International's Short Interest.

How were Intellipharmaceutics International's earnings last quarter?

Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) posted its quarterly earnings results on Monday, July, 16th. The company reported ($0.70) EPS for the quarter, hitting the consensus estimate of ($0.70). The business had revenue of $0.58 million for the quarter, compared to the consensus estimate of $0.90 million.

When did Intellipharmaceutics International's stock split?

Intellipharmaceutics International's stock reverse split on Friday, September 14th 2018. The 1-10 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Intellipharmaceutics International's stock symbol?

Intellipharmaceutics International trades on the OTCMKTS under the ticker symbol "IPCIF."

How do I buy shares of Intellipharmaceutics International?

Shares of IPCIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intellipharmaceutics International's stock price today?

One share of IPCIF stock can currently be purchased for approximately $0.05.

How much money does Intellipharmaceutics International make?

Intellipharmaceutics International (OTCMKTS:IPCIF) has a market capitalization of $1.65 million and generates $1.40 million in revenue each year. The company earns $-5,140,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

How can I contact Intellipharmaceutics International?

Intellipharmaceutics International's mailing address is 30 WORCESTER ROAD, TORONTO A6, M9W 5X2. The official website for the company is www.intellipharmaceutics.com. The company can be reached via phone at 416-798-3001, via email at investors@intellipharmaceutics.com, or via fax at 416-798-3007.

This page (OTCMKTS:IPCIF) was last updated on 3/20/2023 by MarketBeat.com Staff